These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32775494)

  • 1. Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design.
    Ghassemi S; Martinez-Becerra FJ; Master AM; Richman SA; Heo D; Leferovich J; Tu Y; García-Cañaveras JC; Ayari A; Lu Y; Wang A; Rabinowitz JD; Milone MC; June CH; O'Connor RS
    Mol Ther Methods Clin Dev; 2020 Sep; 18():595-606. PubMed ID: 32775494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
    Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
    J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic priming of GD2
    Cappabianca D; Pham D; Forsberg MH; Bugel M; Tommasi A; Lauer A; Vidugiriene J; Hrdlicka B; McHale A; Sodji Q; Skala MC; Capitini CM; Saha K
    bioRxiv; 2024 Mar; ():. PubMed ID: 38562720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.
    Smith C; Økern G; Rehan S; Beagley L; Lee SK; Aarvak T; Schjetne KW; Khanna R
    Clin Transl Immunology; 2015 Jan; 4(1):e31. PubMed ID: 25671129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic priming of GD2
    Cappabianca D; Pham D; Forsberg MH; Bugel M; Tommasi A; Lauer A; Vidugiriene J; Hrdlicka B; McHale A; Sodji QH; Skala MC; Capitini CM; Saha K
    Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101249. PubMed ID: 38699288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
    Cardle II; Cheng EL; Jensen MC; Pun SH
    Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of serum‑free media on the expansion and functionality of CD19.CAR T‑cells.
    Eberhardt F; Hückelhoven-Krauss A; Kunz A; Jiang G; Sauer T; Reichman A; Neuber B; Böpple K; Schmitt A; Müller-Tidow C; Schmitt M; Keib A
    Int J Mol Med; 2023 Jul; 52(1):. PubMed ID: 37264971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Platelet Lysate Media Supplement Supports Lentiviral Transduction and Expansion of Human T Lymphocytes While Maintaining Memory Phenotype.
    Canestrari E; Steidinger HR; McSwain B; Charlebois SJ; Dann CT
    J Immunol Res; 2019; 2019():3616120. PubMed ID: 31565660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
    Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
    Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
    Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
    MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.
    Caruso HG; Tanaka R; Liang J; Ling X; Sabbagh A; Henry VK; Collier TL; Heimberger AB
    J Neurooncol; 2019 Dec; 145(3):429-439. PubMed ID: 31686330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
    Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
    Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
    Front Immunol; 2020; 11():482. PubMed ID: 32528460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells.
    Moseman JE; Foltz JA; Sorathia K; Heipertz EL; Lee DA
    Cytotherapy; 2020 Jun; 22(6):322-328. PubMed ID: 32278551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.